Advancing perioperative treatment in resectable non-small cell lung cancer
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
Data show that mirvetuximab soravtansine-gynx improves outcomes regardless of HRD status
Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
The emerging era of liquid biopsy in endocrine-resistant metastatic breast cancer
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations
First-line use of antibody-drug conjugates: a turning point in metastatic breast cancer
Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending
Tucatinib combo continues to show durable benefit in HER2-mutated metastatic breast cancer
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
Adding adjuvant pertuzumab demonstrates prolonged survival benefit after 10+ years in HER2+ breast cancer
Final long-term overall survival data from APHINITY confirm the efficacy of dual HER2 blockade in patients with node-positive disease
Hortobagyi: “Patient involvement is central to advance research in breast cancer”
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice